drugset / Trial / NCT03760913
OLP-1002 is Being Studied in the Treatment of Pain.
RandomizedParallel-groupTriple-blindTreatment
Summary
The primary objective of the study is to assess the safety and tolerability of single and multiple subcutaneous doses of OLP-1002 in healthy subjects.
Timeline
- Start
- 2018-11-21
- Primary completion
- 2020-10-16
- Completion
- 2020-10-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OLP-1002 | Unknown | 30 ng | Subcutaneous |
| Subject | OLP-1002 | Unknown | 120 ng | Subcutaneous |
| Subject | OLP-1002 | Unknown | 400 ng | Subcutaneous |
| Subject | OLP-1002 | Unknown | 1.2 ug | Subcutaneous |
| Subject | OLP-1002 | Unknown | 2 ug | Subcutaneous |
| Subject | OLP-1002 | Unknown | 3 ug | Subcutaneous |
| Subject | OLP-1002 | Unknown | 5 ug | Subcutaneous |
| Subject | OLP-1002 | Unknown | 6 ug | Subcutaneous |
| Subject | OLP-1002 | Unknown | 10 ug | Subcutaneous |
| Subject | OLP-1002 | Unknown | 12 ug | Subcutaneous |
| Subject | OLP-1002 | Unknown | 20 ug | Subcutaneous |
| Subject | OLP-1002 | Unknown | 40 ug | Subcutaneous |
| Subject | OLP-1002 | Unknown | 80 ug | Subcutaneous |
| Subject | OLP-1002 | Unknown | 160 ug | Subcutaneous |
Indications
No indication recorded.